论文部分内容阅读
目的观察沐舒坦治疗早产儿Ⅰ~Ⅱ级肺透明膜病的应用价值和安全性。方法将28例早产儿Ⅰ~Ⅱ级肺透明膜病随机分为对照组和治疗组,均予鼻塞持续气道正压通气,治疗组在此基础上加用沐舒坦静脉滴注,观察2组治疗后临床症状和胸片的改善情况。结果治疗组在临床症状和胸片的改善情况均优于对照组,生命体征无异常改变。结论沐舒坦治疗早产儿Ⅰ~Ⅱ级肺透明膜病可改善早产儿的临床症状,改善氧合,改善胸片情况,且无明确不良反应,是安全、有效的治疗方法。
Objective To observe the application value and safety of Mucosolvan in the treatment of Ⅰ ~ Ⅱ grade hyaline membrane disease in premature infants. Methods 28 cases of grade Ⅰ ~ Ⅱ hyaline membrane disease of preterm infants were randomly divided into control group and treatment group. All patients were given continuous positive airway pressure through nasal obstruction. On the basis of this, Clinical symptoms and improvement of chest radiograph after treatment. Results The improvement of clinical symptoms and chest radiograph in the treatment group was better than that in the control group, with no abnormal changes in vital signs. Conclusion Mucosolvan in the treatment of preterm infants Ⅰ ~ Ⅱ hyaline membrane disease can improve the clinical symptoms of premature infants, improve oxygenation and improve chest radiography, and no clear adverse reactions, is a safe and effective treatment.